News FDA backs Novartis' Gilenya in paediatric MS First disease modifying therapy approved in paediatric MS
News Novartis paid $1.2m to Trump lawyer for policy insights Special counsel also contacted pharma over Trump's Russian links
News Novartis matches Gilead on price in new CAR-T use Novartis won't offer 'money back' scheme because of delayed effect
News Novartis app could revolutionise ophthalmic clinical trials Patients will be able to participate in clinical ophthalmology trials from home thanks to a groundbreaking digital app developed by Novartis.
News Novartis and Pear to develop substance use digital therapeut... Novartis is set to develop and commercialise a range of digital therapeutics for patients with substance and opioid use disorders as it expands its work with Pear Therapeutics through a dea
News Novartis/Amgen migraine jab works in tough-to-treat patients Novartis continues to build the case for its Aimovig migraine injection,with data showing it works in a tough-to-treat patient group.
News Angelini Pharma's R&D chief heads for the exit Dr Rafal Kaminski's near five-year tenure as chief scientific officer of Italy's Angelini Pharma will come to an end in the next couple of weeks.
Sales & Marketing Sponsored Securing your ROI: Turning post-acquisition integration into... Join Forinnovia and Little Cube Consulting for a webinar on securing post-acquisition ROI.